TABLE 2.
Regression analyses between pre-HT levels of plasma proteins measured in normalized protein expression scale, expressed in AU, and post-HT T score from the lumbar spine (A) and femoral neck (B). a Adjusted with Benjamini & Hochberg (false discovery rate) correction.
| (A) Plasma protein | β | (95% CI) | p | Adjusted p a |
|---|---|---|---|---|
| FGF23 | 1.72 | (1.33; 2.22) | <0.001* | 0.011* |
| Osteopontin | 2.44 | (1.40; 4.27) | 0.005* | 0.066 |
| Osteoprotegerin | 3.21 | (1.30; 7.91) | 0.018* | 0.111 |
| Perlecan | 2.24 | (1.22; 4.11) | 0.016* | 0.111 |
| RANK | 2.02 | (1.17; 3.49) | 0.019* | 0.111 |
| COL1A1 | 2.20 | (1.14; 4.27) | 0.028* | 0.135 |
| ITGB2 | 2.18 | (1.03; 4.63) | 0.053 | 0.219 |
| Melusin | 1.22 | (1.00; 1.50) | 0.066 | 0.240 |
| WISP1 | 1.78 | (0.94; 3.36) | 0.087 | 0.258 |
| ITGB5 | 2.32 | (0.92; 5.88) | 0.089 | 0.258 |
| Stromelysin-1 | 1.51 | (0.93; 2.43) | 0.107 | 0.259 |
| MEPE | 1.79 | (0.91; 3.54) | 0.106 | 0.259 |
| MMP2 | 2.59 | (0.80; 8.42) | 0.126 | 0.261 |
| MMP9 | 1.52 | (0.92; 2.51) | 0.117 | 0.261 |
| Prolargin | 3.43 | (0.64; 18.40) | 0.164 | 0.317 |
| Syndecan-1 | 1.71 | (0.79; 3.70) | 0.184 | 0.334 |
| Matrilysin | 1.39 | (0.78; 2.47) | 0.270 | 0.459 |
| TIMP4 | 1.48 | (0.73; 2.99) | 0.285 | 0.459 |
| Osteonectin | 2.10 | (0.46; 9.58) | 0.349 | 0.533 |
| Glypican-1 | 1.60 | (0.54; 4.72) | 0.403 | 0.584 |
| ITGAV | 1.85 | (0.35; 9.80) | 0.478 | 0.660 |
| Cadherin-5 | 1.38 | (0.47; 4.07) | 0.566 | 0.746 |
| Decorin | 1.25 | (0.50; 3.13) | 0.631 | 0.766 |
| HOSCAR | 1.52 | (0.28; 8.32) | 0.634 | 0.766 |
| TR-AP | 0.83 | (0.32; 2.16) | 0.703 | 0.778 |
| Thrombospondin-2 | 0.79 | (0.22; 2.90) | 0.724 | 0.778 |
| MMP12 | 1.08 | (0.76; 1.54) | 0.681 | 0.778 |
| GPNMB | 1.11 | (0.16; 7.57) | 0.917 | 0.950 |
| CCN1 | 1.00 | (0.41; 2.44) | 0.994 | 0.994 |
| (B) Plasma protein | ||||
| Melusin | 1.15 | (1.02; 1.28) | 0.029* | 0.758 |
| GPNMB | 0.40 | (0.14; 1.12) | 0.095 | 0.758 |
| HOSCAR | 0.44 | (0.18; 1.12) | 0.100 | 0.758 |
| ITGB5 | 1.54 | (0.90; 2.66) | 0.130 | 0.758 |
| Osteopontin | 1.33 | (0.92; 1.92) | 0.138 | 0.758 |
| COL1A1 | 1.35 | (0.90; 2.03) | 0.159 | 0.758 |
| Thrombospondin-2 | 0.60 | (0.29; 1.24) | 0.183 | 0.758 |
| FGF23 | 1.10 | (0.91; 1.33) | 0.313 | 0.947 |
| Syndecan-1 | 0.82 | (0.52; 1.29) | 0.405 | 0.947 |
| MMP12 | 0.92 | (0.75; 1.13) | 0.436 | 0.947 |
| ITGB2 | 1.19 | (0.75; 1.90) | 0.465 | 0.947 |
| TR-AP | 0.82 | (0.47; 1.41) | 0.478 | 0.947 |
| Prolargin | 0.72 | (0.26; 1.96) | 0.525 | 0.947 |
| Osteonectin | 1.33 | (0.55; 3.23) | 0.531 | 0.947 |
| Stromelysin-1 | 1.08 | (0.81; 1.44) | 0.618 | 0.947 |
| Cadherin-5 | 0.86 | (0.46; 1.61) | 0.642 | 0.947 |
| MMP9 | 1.07 | (0.79; 1.45) | 0.682 | 0.947 |
| MEPE | 0.92 | (0.61; 1.39) | 0.696 | 0.947 |
| CCN1 | 1.11 | (0.66; 1.85) | 0.704 | 0.947 |
| Perlecan | 0.93 | (0.63; 1.38) | 0.732 | 0.947 |
| Osteoprotegerin | 1.10 | (0.61; 1.97) | 0.760 | 0.947 |
| ITGAV | 1.16 | (0.44; 3.06) | 0.767 | 0.947 |
| Matrilysin | 0.96 | (0.68; 1.34) | 0.799 | 0.947 |
| Glypican-1 | 0.93 | (0.49; 1.75) | 0.816 | 0.947 |
| RANK | 1.04 | (0.73; 1.49) | 0.819 | 0.947 |
| Decorin | 1.04 | (0.62; 1.77) | 0.874 | 0.947 |
| WISP1 | 1.02 | (0.69; 1.51) | 0.913 | 0.947 |
| MMP2 | 0.97 | (0.48; 1.99) | 0.941 | 0.947 |
| TIMP4 | 0.99 | (0.65; 1.49) | 0.947 | 0.947 |
Adjusted with Benjamini & Hochberg (false discovery rate) correction.
AU, arbitrary units; CCN1, CCN family member 1; CI, confidence interval; COL1A1, collagen alpha-1(I) chain; FGF23, fibroblast growth factor 23; ITGAV, integrin alpha-V; ITGB2, integrin beta-2; ITGB5, integrin beta-5; MEPE, matrix extracellular phosphoglycoprotein; MMP, matrix metalloproteinase; TIMP4, metalloproteinase inhibitor 4; hOSCAR, osteoclast-associated immunoglobulin-like receptor; RANK, receptor activator of nuclear factor κ-B; TR-AP, tartrate-resistant acid phosphatase type 5; GPNMB, transmembrane glycoprotein NMB; WISP1, WNT1-inducible-signaling pathway protein 1. *Indicates statistical significance.